Halozyme Therapeutics (HALO) reported $298.01 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 29.6%. EPS of $1.26 for the same period compares to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback